The Board of Directors of Evonile Pharma Limited (formally known as Novartis India Limited) has approved the raising of funds by way of Rights Issue at their Board Meeting held today i.e. October 08, 2026.

Evonile Pharma Limited (formerly known as Novartis India Limited) October 08, 2026 BSE Limited The Secretary, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. BSE Scrip Code: 500672 Subject: Outcome of the Meeting of the Board of Directors held on October 08, 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors (“Board”) of Evonile Pharma Limited (formerly known as Novartis India Limited) (“Company”), at its meeting held today, i.e., October 08, 2026, inter alia, considered and approved the following matters: 1. Approval for Raising of Funds by way of Rights Issue Approved raising of funds through the issuance and allotment of partly paid-up equity shares of the Company having face value of ₹5/- each, for an aggregate amount not exceeding ₹9,000 million (Rupees Nine Thousand Million only), on a rights basis on such terms and conditions as may be decided by the Board to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently) subject to receipt of applicable statutory and regulatory approvals and in accordance with the provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI Listing Regulations and the rules made thereunder, as amended from time to time and other applicable laws. The details required under Regulation 30 of the SEBI Listing Regulations read with master circular bearing reference no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, as amended from time to time, is enclosed as Annexure A. Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) 2. Constitution of Rights Issue Committee Approved the constitution of a Rights Issue Committee comprising of Mr. Vikas Gupta – Managing Director and Chief Executive Officer, Dr. Jagriti Gupta – Non Executive Director and Mr. Shashank Sinha – Independent Director, of the Company and delegated authority to the Committee to determine and finalize the detailed terms and conditions of the Rights Issue, including but not limited to the issue size, rights entitlement ratio, issue price, record date, timing of the issue, allotment of shares, appointment of intermediaries and all other related matters. 3. Approval of Postal Ballot Notice Approved the notice of Postal Ballot for seeking approval of the Shareholders of the Company. 4. Approved adoption and launch of the new corporate website of the Company under the name of Evonile Pharma Limited. The website of the Company shall be www.evonilepharma.com The meeting of the Board of Directors commenced at 04:40 PM IST and concluded at 5:31 PM IST. The above information shall also be available on the new website of the Company at www.evonilepharma.com Kindly take the above information on records. Thank you, Yours faithfully, For Evonile Pharma Limited (formerly known as Novartis India Limited) Chandni Maru Company Secretary and Compliance Officer M. No. A60291 Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) Annexure- A Sr. Particulars Details 1. Type of securities proposed to be Equity Shares (Partly paid-up) issued 2. Type of issuance Rights Issue 3. Total number of securities Issue of such number of securities at such a proposed to be issued or the total price and on such terms, as decided by the amount for which the securities will Board or the Rights Issue Committee of the be issued (approximately) Board, at a later date, for an aggregate amount not exceeding ₹ 9,000 Million (Indian Rupees Nine Thousand Million only) on Rights issue basis, to the eligible equity shareholders. 4. Any cancellation or termination of Not Applicable proposal for issuance of securities including reasons thereof Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.evonilepharma.com